Filing Flows

Filing Flows › Crispr Therapeutics AG (CRSP) › Next earnings date

Crispr Therapeutics AG (CRSP) earnings: missed the estimate

Crispr Therapeutics AG (CRSP) reported on Nov 2, 2026 and missed the EPS estimate: −$1.15 against −$1.06 (-8.5%). Revenue was $12.7M for Q3 2026, 14× year over year. It beat the EPS estimate in 40% of the quarters on record.

Last result−8.5% vs estimate
Beat rate40%

The last report

Crispr Therapeutics AG reported revenue of $12.7M for the third quarter 2026 (14× Y/Y), net loss $111M: Collaboration Revenue $12.3M, Grant $346K. How it makes money → · Every quarter →

Crispr Therapeutics AG: EPS against the estimate, last 5 reportsCrispr Therapeutics AG: EPS against the estimate, last 5 reportsEstimateReported−$1.29−$1.17Nov 25−$1.23−$1.37Feb 26−$1.23−$1.28May 26−$1.18−$0.94Aug 26−$1.06−$1.15Nov 26
Latest (Nov 26): Estimate −$1.06, Reported −$1.15.

Crispr Therapeutics AG's latest quarter

Crispr Therapeutics AG, Q3 2026: revenue $12.7M (14× year over year), net loss $111M, operating cash flow −$89.7M. The chart follows the revenue to costs, profit and cash.

Questions

Did Crispr Therapeutics AG beat earnings?

Crispr Therapeutics AG (CRSP) reported on Nov 2, 2026 and missed the EPS estimate: −$1.15 against −$1.06 (-8.5%).

When does CRSP report earnings?

The next date is not set yet.

Does Crispr Therapeutics AG usually beat earnings?

It beat the consensus EPS estimate in 40% of the quarters on record.

Open the interactive view →

Updated Nov 8, 2026. Read automatically from SEC filings and public data; errors are possible. Not investment advice.